Join
Live feed
·
PRReleasevia Quantisnow
Nurix Therapeutics Inc. logo

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

ByQuantisnow·Wall Street's wire, on your screen.
NRIX· Nurix Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NRIX (Nurix Therapeutics Inc.) and more on Quantisnow.